Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase EARLY_PHASE1 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 16OTHER 8NETWORK 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Plasmablastic Lymphoma 1

Interventions

Specimen Handling 16Magnetic Resonance Spectroscopy 13Vincristine 8Dexamethasone 6Cyclophosphamide 6Radiotherapy 5Radiation 5Leucovorin 5Lenalidomide 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5dexamethasone acetate 4dexamethasone 21-phosphate 4daratumumab 4auricularum 4X-Rays 4Standard of Care 4Radiotherapy, Conformal 4Practice Guidelines as Topic 4Etoposide 4Cytarabine 4Bortezomib 4Biopsy 4pegaspargase 3Taxes 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Prednisone 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × daratumumab × 30 days × Clear all
NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AIDS Malignancy Consortium

Phase EARLY_PHASE1 Recruiting
15 enrolled
Lymphoid

Plasmablastic Lymphoma

NCT06918002 2026-06-01

ElLen

Intergroupe Francophone du Myelome

Phase 3 Recruiting
824 enrolled
Plasma cell

Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Eastern Cooperative Oncology Group

Phase 3 Recruiting
1,450 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡